HIV Vaccine Research in Canada

Overview

Journal AIDS Res Ther

Publisher Biomed Central

Specialty Infectious Diseases

Date 2017 Sep 13

PMID 28893293

Authors

Robin Shattock

Affiliations

Soon will be listed here.

References

Sanders R, Derking R, Cupo A, Julien J, Yasmeen A, de Val N . A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 2013; 9(9):e1003618. PMC: 3777863. DOI: 10.1371/journal.ppat.1003618. View

Mylvaganam G, Silvestri G, Amara R . HIV therapeutic vaccines: moving towards a functional cure. Curr Opin Immunol. 2015; 35:1-8. PMC: 4553139. DOI: 10.1016/j.coi.2015.05.001. View

Chen J, Kovacs J, Peng H, Rits-Volloch S, Lu J, Park D . HIV-1 ENVELOPE. Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein. Science. 2015; 349(6244):191-5. PMC: 4701381. DOI: 10.1126/science.aaa9804. View

Stewart-Jones G, Soto C, Lemmin T, Chuang G, Druz A, Kong R . Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G. Cell. 2016; 165(4):813-26. PMC: 5543418. DOI: 10.1016/j.cell.2016.04.010. View

Stephenson K, DCouto H, Barouch D . New concepts in HIV-1 vaccine development. Curr Opin Immunol. 2016; 41:39-46. PMC: 4992607. DOI: 10.1016/j.coi.2016.05.011. View

Theiler J, Yoon H, Yusim K, Picker L, Fruh K, Korber B . Epigraph: A Vaccine Design Tool Applied to an HIV Therapeutic Vaccine and a Pan-Filovirus Vaccine. Sci Rep. 2016; 6:33987. PMC: 5050445. DOI: 10.1038/srep33987. View

Li H, Omange R, Plummer F, Luo M . A novel HIV vaccine targeting the protease cleavage sites. AIDS Res Ther. 2017; 14(1):51. PMC: 5594498. DOI: 10.1186/s12981-017-0174-7. View

Kang C, Gao Y . Killed whole-HIV vaccine; employing a well established strategy for antiviral vaccines. AIDS Res Ther. 2017; 14(1):47. PMC: 5594480. DOI: 10.1186/s12981-017-0176-5. View

Holder K, Grant M . Modulation of the strength and character of HIV-specific CD8 T cell responses with heteroclitic peptides. AIDS Res Ther. 2017; 14(1):41. PMC: 5594471. DOI: 10.1186/s12981-017-0170-y. View

10.

Richard J, Ding S, Finzi A . Unlocking HIV-1 Env: implications for antibody attack. AIDS Res Ther. 2017; 14(1):42. PMC: 5594528. DOI: 10.1186/s12981-017-0168-5. View

11.

Racine T, Kobinger G, Arts E . Development of an HIV vaccine using a vesicular stomatitis virus vector expressing designer HIV-1 envelope glycoproteins to enhance humoral responses. AIDS Res Ther. 2017; 14(1):55. PMC: 5594459. DOI: 10.1186/s12981-017-0179-2. View

12.

Ahmed Y, Tian M, Gao Y . Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies. AIDS Res Ther. 2017; 14(1):50. PMC: 5594608. DOI: 10.1186/s12981-017-0178-3. View

13.

Pankrac J, Klein K, Mann J . Eradication of HIV-1 latent reservoirs through therapeutic vaccination. AIDS Res Ther. 2017; 14(1):45. PMC: 5594457. DOI: 10.1186/s12981-017-0177-4. View

14.

Baxter A, Niessl J, Morou A, Kaufmann D . RNA flow cytometric FISH for investigations into HIV immunology, vaccination and cure strategies. AIDS Res Ther. 2017; 14(1):40. PMC: 5594475. DOI: 10.1186/s12981-017-0171-x. View

15.

Liu J, Ostrowski M . Development of targeted adjuvants for HIV-1 vaccines. AIDS Res Ther. 2017; 14(1):43. PMC: 5594534. DOI: 10.1186/s12981-017-0165-8. View

16.

Vitali D, Wessels J, Kaushic C . Role of sex hormones and the vaginal microbiome in susceptibility and mucosal immunity to HIV-1 in the female genital tract. AIDS Res Ther. 2017; 14(1):39. PMC: 5594427. DOI: 10.1186/s12981-017-0169-4. View

17.

Prodger J, Kaul R . The biology of how circumcision reduces HIV susceptibility: broader implications for the prevention field. AIDS Res Ther. 2017; 14(1):49. PMC: 5594533. DOI: 10.1186/s12981-017-0167-6. View

18.

Bernard N . Natural killer (NK) cell receptor-HLA ligand genotype combinations associated with protection from HIV infection: investigation of how protective genotypes influence anti HIV NK cell functions. AIDS Res Ther. 2017; 14(1):38. PMC: 5594513. DOI: 10.1186/s12981-017-0172-9. View

19.

Routy J, Mehraj V . Potential contribution of gut microbiota and systemic inflammation on HIV vaccine effectiveness and vaccine design. AIDS Res Ther. 2017; 14(1):48. PMC: 5594512. DOI: 10.1186/s12981-017-0164-9. View

20.

Grant M, Larijani M . Evasion of adaptive immunity by HIV through the action of host APOBEC3G/F enzymes. AIDS Res Ther. 2017; 14(1):44. PMC: 5594601. DOI: 10.1186/s12981-017-0173-8. View